Patients with Hodgkin Lymphoma, we need your help!
If you were newly diagnosed with Hodgkin Lymphoma and have been treated with Brentuximab vedotin containing regimen (BrECADD) you can help by completing our survey.
Lymphoma Canada is preparing a submission for Canada’s Drug Agency (CDA). This survey provides us with the patient input required for the submission. CDA uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs
The therapy that will soon be reviewed by the CDA is the Brentuximab vedotin containing regimen (BrECADD), which includes etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, for newly diagnosed Hodgkin Lymphoma patients.
You do not need to live in Canada to complete this survey. You can still participate in this survey if you are a Hodgkin Lymphoma patient who has not received this therapy.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
It should only take between 15-20 minutes of your time.
Please share and help us spread the word.
Thank you for your support.
Please share and help us spread the word.
Thank you for your support.
